2E,4E,8Z,10E-dodecatetraenoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2E,4E,8Z,10E-dodecatetraenoic acid
• 英文别名: (2E,4E,8Z,10E)-dodeca-2,4,8,10-tetraenoic acid
• 化学式: C₁₂H₁₆O₂
• 分子量: 192.25
• InChiKey: RUQFLFFSSDCHKE-CRIHJKBTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Compositions and Methods Comprising Zingiber Species
  申请人：Li Dan

  公开号：US20080160116A1

  公开（公告）日：2008-07-03

  An aspect of the present invention relates to compositions comprising a gingerol, for example, compositions comprising gingerol in an amount greater than about 2% by weight. In some aspects of the invention, the composition comprises 6-gingerol, 8-gingerol, 10-gingerol, 6-shagaol, or combinations thereof. Another aspect of the invention relates to a method for extracting a ginger species comprising, sequentially extracting a ginger species plant material to yield an essential oil fraction, a gingerol fraction, a phenolic fraction, and a polysaccharide fraction, wherein the essential oil and gingerol fractions are derived by extracting plant feedstock material by supercritical carbon dioxide extraction, the phenolic fraction is extracted from the plant feedstock material or from the remainder of the essential oil and gingerol extractions by hydroalcoholic extraction, and the polysaccharide fraction is derived by water extraction of the remainder of the phenolic extraction.
• INHIBITORS OF ANOREXIC LIPID HYDROLYSIS FOR THE TREATMENT OF EATING DISORDERS
  申请人：Hansen Harald S.

  公开号：US20090054526A1

  公开（公告）日：2009-02-26

  Compounds, pharmaceuticals, cosmetic or dietary supplements for the treatment of overweight, obesity and/or type II diabetes in a mammal (e.g. human) comprising a compound with formula I or formula II for example ceramidase-inhibitor, such as (1S,2R)-D-ery-thro-2-(N-myristoylamino)-1-phenyl-1-propanol, alone or in combination with an anorexic lipid (or other appetite-inhibiting acylamides or oleoyl-estrone), and methods of treatment comprising administration of said compounds, pharmaceuticals, cosmetic or a dietary supplements. The compounds, pharmaceuticals, cosmetic or dietary supplements and methods of the invention may further be used in modifying the feeding behaviour, suppression of hunger, enhancement of satiety, reduction of energy intake, reduction of fat tissue mass/lean mass ratio in a mammal (e.g. human).
• (17-ß)-3-OXOANDROST-4-EN-17-YL UNDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
  申请人：Lipocine Inc.

  公开号：US20160193225A1

  公开（公告）日：2016-07-07

  Disclosed herein are compositions having a lipophilic active agent and methods of their use.
• PHARMACEUTICAL COMPOSITION AND METHODS
  申请人：Lipocine Inc.

  公开号：US20160184324A1

  公开（公告）日：2016-06-30

  Disclosed herein are compositions having a lipophilic active agent and methods of their use.
• (17-ß)-3-Oxoandrost-4-En-17-Yl Undecanoate Compositions and Methods of Their Preparation and Use
  申请人：Lipocine Inc.

  公开号：US20180104257A1

  公开（公告）日：2018-04-19

  Disclosed herein are compositions having a lipophilic active agent and methods of their use.